ArticleInfection and immunity2002
Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 65 citations in OpenAlex.
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- The Expanding Mycovirome ofJournal of fungi (Basel, Switzerland) · 2024Review
- A Novel Monoclonal Antibody 1D2 That Broadly Inhibits Clinically ImportantJournal of fungi (Basel, Switzerland) · 2022Article
- Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.International journal of molecular sciences · 2022Review
- Experimental Models of Infectious Pulmonary Complications Following Hematopoietic Cell Transplantation.Frontiers in immunology · 2021Review
- Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies.Journal of fungi (Basel, Switzerland) · 2020Review
- Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020Review
- Immunomodulation as a Therapy forJournal of fungi (Basel, Switzerland) · 2018Review
- Review
- The Biology of Pichia membranifaciens Killer Toxins.Toxins · 2017Review
- Rodent Models of Invasive Aspergillosis due toFrontiers in microbiology · 2017Review
- Aspergillosis and stem cell transplantation: An overview of experimental pathogenesis studies.Virulence · 2016Review
- The protective role of immunoglobulins in fungal infections and inflammation.Seminars in immunopathology · 2015Review
- Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases.Frontiers in microbiology · 2015Review
- Antibody Peptide based antifungal immunotherapy.Frontiers in microbiology · 2012Article
- Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin.Antimicrobial agents and chemotherapy · 2010Article
- Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities.PloS one · 2008Article
- Review
- Immunosuppressive effects of CCL17 on pulmonary antifungal responses during pulmonary invasive aspergillosis.Infection and immunity · 2005Article
- Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis.Clinical and diagnostic laboratory immunology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiidiotypic monoclonal antibodies (MAbs) representing the internal image of a yeast killer toxin (KT) have therapeutic potential against several fungal infections. The efficacy of KT MAbs against Aspergillus fumigatus was investigated in a mouse model of T-cell-depleted allogeneic bone marrow transplantation (BMT) with invasive pulmonary aspergillosis. Mice were highly susceptible to infection at 3 days post-BMT, when profound neutropenia was observed both in the periphery and in the lungs. Treatment with KT MAbs protected the mice from infection, as judged by the long-term survival and decreased pathology associated with inhibition of fungal growth and hyphal development in the lungs. In vitro, similar to polymorphonuclear neutrophils, KT MAbs significantly inhibited the hyphal development and metabolic activity of germinated Aspergillus conidia. These results indicate that mimicking the action of neutrophils could be a strategy through which KT MAbs exert therapeutic efficacy in A. fumigatus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.